The FDA has approved 75- and 150-milligram capsules of Boehringer Ingelheim's blood thinner Pradaxa to prevent stroke in patients with atrial fibrillation. "Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," an FDA official said.

Full Story:

Related Summaries